Co-Authors
This is a "connection" page, showing publications co-authored by Jeff Slezak and Sara Tartof.
Connection Strength
2.969
-
Rate and severity of suspected SARS-Cov2 reinfection in a cohort of PCR-positive COVID-19 patients. Clin Microbiol Infect. 2021 Jul 28.
Score: 0.791
-
BNT162b2 against COVID-19-associated Emergency Department and Urgent Care Visits among Children 5-11 Years of Age: a Test Negative Design. J Pediatric Infect Dis Soc. 2023 Jan 28.
Score: 0.220
-
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System. JAMA Netw Open. 2023 Jan 03; 6(1):e2251833.
Score: 0.219
-
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis. 2022 12; 22(12):1663-1665.
Score: 0.216
-
Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Lancet Respir Med. 2023 Feb; 11(2):176-187.
Score: 0.215
-
Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years. JAMA Netw Open. 2022 08 01; 5(8):e2225162.
Score: 0.212
-
Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants. Lancet Respir Med. 2022 07; 10(7):e61-e62.
Score: 0.209
-
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022 Apr 22.
Score: 0.208
-
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. Lancet Reg Health Am. 2022 Feb 14; 100198.
Score: 0.206
-
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021 10 16; 398(10309):1407-1416.
Score: 0.200
-
Safety of Quadrivalent Meningococcal Conjugate Vaccine in Children 2-10 Years. Pediatr Infect Dis J. 2017 Nov; 36(11):1087-1092.
Score: 0.153
-
Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old. Vaccine. 2020 01 10; 38(2):228-234.
Score: 0.044
-
Validity of ICD-10-CM codes for determination of diabetes type for persons with youth-onset type 1 and type 2 diabetes. BMJ Open Diabetes Res Care. 2019; 7(1):e000547.
Score: 0.042
-
Safety of Quadrivalent Meningococcal Conjugate Vaccine in 11- to 21-Year-Olds. Pediatrics. 2017 01; 139(1).
Score: 0.036